Pemvidutide is a Synthetic Peptide owned by Altimmune, and is involved in 8 clinical trials, of which 3 were completed, 4 are ongoing, and 1 is planned.

ALT-801 is a highly efficacious agonist at both the GLP-1 and glucagon receptor. It enhances glucose-dependent insulin secretion by the pancreatic beta-cells, suppresses inappropriately elevated glucagon secretion and slows gastric emptying. It binds to and activates the human GLP-1 receptor exhibiting anti-hyperglycemic actions by mechanisms involving cyclic AMP or other intracellular signaling pathways.

The revenue for Pemvidutide is expected to reach a total of $2.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Pemvidutide NPV Report.

Pemvidutide was originated by Velocity Pharmaceutical Development and is currently owned by Altimmune.

Pemvidutide Overview

Pemvidutide (ALT-801) is under development for the treatment of obesity, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease and type 2 diabetes. The drug candidate is administered subcutaneously. It is a synthetic peptide and is an analogue of oxyntomodulin. The drug candidate targets GLP-1 and glucagon receptor. It is developed based on EuPort technology. 

Altimmune Overview

Altimmune, is a a biopharmaceutical company. It focuses on developing liver disease and immune modulating therapies. The company’s pipeline products include ALT-801, a glucagon receptor to treat metabolic dysfunction that leads to non-alcoholic steatohepatitis (NASH). Altimmune also offers nasovax, an intranasally administered recombinant influenza vaccine; and heptcell, an immunotherapy to patients chronically infected with the hepatitis B virus; nasoshield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores. In addition, its products find its application in the treatment of acute respiratory infections, chronic viral infections, and cancer. Altimmune is headquartered in Gaithersburg, Maryland, the US.

The company reported revenues of (US Dollars) US$4.4 million for the fiscal year ended December 2021 (FY2021), a decrease of 46.1% over FY2020. The operating loss of the company was US$96.9 million in FY2021, compared to an operating loss of US$54.8 million in FY2020. The net loss of the company was US$97.1 million in FY2021, compared to a net loss of US$49 million in FY2020.

Quick View – Pemvidutide

Report Segments
  • Innovator
Drug Name
  • Pemvidutide
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Gastrointestinal
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.